Past Funding Opportunities
Cancer Moonshot Biobank Biospecimen Core Resource RFP
In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Biospecimen Core Resource (BCR). The BCR will have responsibility for shipment of biospecimen collection kits; receipt of biospecimens; processing specimens (e.g. histological sectioning, staining, imaging) for pathology review; storage and tracking of biospecimens; extraction of nucleic acids; and shipment of biospecimens and their derivatives to appropriate laboratories and researchers.
Questions due 2/21/19; Bidder’s teleconference 2/28/19; Proposals due 3/18/19.
https://frederick.cancer.gov/workwithus/solicitations/s19-054
Cancer Moonshot Biobank Patient and Provider Engagement (PPE) Portal RFP
In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Patient and Provider Engagement (PPE) Portal. This effort will develop and deploy a web portal that meets the needs of patients, their family members, their healthcare providers, and medical institutions. The PPE portal will have an open access site to allow anyone learn about the project and will also have a secure section for authenticated users.
Questions due 2/15/19; Bidder’s teleconference 3/21/19; Proposals due 4/8/19.
https://frederick.cancer.gov/workwithus/solicitations/s19-053
Cancer Moonshot Biobank e-consent RFP
In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for an electronic informed consent tool to allow participants at up to 150 different sites to electronically consent to participate in the Cancer Moonshot Biobank project. The eConsent tool will be accessed with a standard web browser on the world wide web.
https://frederick.cancer.gov/workwithus/solicitations/s19-003
Cancer Moonshot Biobank Biospecimen Source Site Coordinator (BSSC) RFP
In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., has issued Requests for Proposals for a Biospecimen Source Site Coordinator (BSSC) who will be responsible for training, coordinating, and assisting Biospecimen Source Sites (BSSs). The BSSC will provide reimbursement to the BSSs for biospecimen and data acquisition as well as other activities as needed.
https://frederick.cancer.gov/workwithus/solicitations/s18-087
Cancer Moonshot Biobank Project - Institutional Review Board (IRB)
In support of the Cancer Moonshot Biobank, Leidos Biomedical Research, Inc., seeks a subcontractor to carry out the IRB review requirements as specified under the Health and Human Services (HHS) regulations at 45 Code of Federal Regulations (CFR) part 46. There are two main tasks required for this project: 1) to serve as a single IRB for up to 150 participating Biospecimen Source Sites (BSS), and 2) to serve as the IRB for the Biospecimen Core Resource (BCR). Proposal Due Date: Wednesday, September 5, 2018.
https://frederick.cancer.gov/workwithus/solicitations/s18-095
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)
PAR-16-166
Posted date: April 5, 2016; Expiration date: June 23, 2017
Application receipt dates: June 22, 2016; February 13, 2017; October 11, 2017; June 22, 2018, by 5:00 PM local time of applicant organization.
This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development due to preanalytical variability in tissue biopsy biospecimens. The program will tie in with current efforts to optimize clinical biomarker assays utilized in NCI-sponsored clinical trials. Results from this research program will improve the understanding of how biopsy collection, processing, and storage procedures may affect assay detection limits for current and emerging clinical biomarkers, as well as expedite clinical biomarker assay development through the evidence-based standardization of biopsy handling practices.
The FOA will fund multidisciplinary teams that will constitute a collaborative network using a U01 Cooperative Agreement. Each team's application will focus on specific biomarker assays and associated questions in biospecimen science, and present a research plan for acquiring the needed biospecimens. Multidisciplinary scientific teams will be involved, including pathologists, oncologists, radiologists, molecular biologists, and statisticians, as the work requires expertise and perspectives in clinical medicine, knowledge of the unique issues related to obtaining biopsy biospecimens, biology and technology platforms, and experimental design and analysis. These teams must include investigators currently involved in NCI Phase I and Phase II clinical trials. Projects will involve defining workable biospecimen conditions for trials that utilize a particular type of biopsy (e.g. lung aspirates, liver biopsies) in a biomarker assay system (e.g. NGS for mutation-targeted drug trials; multi-analyte IHC/IFA or targeted mass spec for PD assays/pathway analysis) to detect emerging clinical biomarkers.
https://grants.nih.gov/grants/guide/pa-files/PAR-16-166.html
CDP contact: Dr. Abhi Rao, 240-276-5715, abhi.rao@mail.nih.gov
ARRA Funding Opportunity: cancer Human Biobank (caHUB) Comprehensive Data Resource
New Receipt Date: Nov. 10, 2010, 2:00 p.m. EDT
Preproposal Teleconference: Oct. 20, 2010, 2:00-3:30 p.m. EDT; 1-800-366-7242, Passcode: 6065589#
A subcontract solicitation has been posted on Federal Business Opportunities by NCI’s contractor, SAIC-Frederick. The Solicitation is in support of the NCI cancer Human Biobank (caHUB) initiative and a request for proposals (RFP) for a comprehensive data resource. The RFP is located at the Federal Business Opportunities website under Solicitation Number ST10-1124. This funding is made available under the American Recovery and Reinvestment Act of 2009 (Recover Act), Pub. L. No. 111-5.
A preproposal teleconference will be held by SAIC-F on Oct. 10, 2010, from 2:00-3:30 p.m. EDT. This call will provide offerors the opportunity to ask questions about the RFP and receive answers during the teleconference. Please call 1-800-366-7242, Passcode: 6065589# to join.
Proposals must be submitted by Nov. 10, 2010.
For questions regarding this RFP, please email SAIC-F, attention Carol Caballero.
Small Business Funding Opportunity: Alternative Biospecimen Stabilization and Storage Solutions
SBIR Contract Solicitation PHS 2011-1
Topic: #284 Alternative Biospecimen Stabilization and Storage Solutions
Deadline: Nov. 8, 2010
Number of anticipated awards: 1-2
Budget (total costs): Phase I: $150,000 for 9 months; Phase II: $1,000,000 for 2 years
The NCI Small Business Innovation Research Development Center is seeking contract proposals from small businesses in response to a funding opportunity to develop alternative biospecimen stabilization and storage solutions. Small businesses developing novel, innovative, or improved methodology(ies) or reagent(s) for the stabilization and/or storage of cancer tissue biospecimens and their resulting molecular analytes are encouraged to apply.
NCI is interested in proposals that demonstrate how the product will overcome limitations and disadvantages of current biospecimen stabilization and storage methods intended for use in molecular research, namely formalin-fixed paraffin embedded and frozen tissues. The project scope could include reagents and/or novel methodologies for biospecimen fixation, biospecimen storage and short term post operative biospecimen stabilization for tissue evaluation and/or transport. Review the funding opportunity.
ARRA Funding Opportunity: cancer Human Biobank (caHUB) Biospecimen Source Sites
New Receipt Date: Nov. 1, 2010, 2:00 p.m. EDT
A subcontract solicitation has been posted on Federal Business Opportunities by NCI’s contractor, SAIC-Frederick. The Solicitation is in support of the NCI cancer Human Biobank (caHUB) initiative and a request for proposals(RFP) for biospecimen source sites. The RFP is located at the Federal Business Opportunities website under Solicitation Number ST10-1105.
This funding is made available under the American Recovery and Reinvestment Act of 2009 (Recover Act), Pub. L. No. 111-5.
Proposals must be submitted by Nov. 2, 2010, 2:00 p.m. EDT.
For questions regarding this RFP, please email SAIC-F, attention Aroussiak "Rue" Bowen.
ARRA Funding Opportunity: caHUB Comprehensive Biospecimen Resource
Pre-proposal Teleconference: June 1, 2010, 1:00-3:00 p.m. EDT
Receipt Date: June 17, 2010, 2:00 p.m. EDT
Written Q & A: Questions may be submitted in writing to Jennifer Thomas at no later than 2 p.m. (EDT) on May 14, 2010
The National Cancer Institute’s (NCI) Office of Biorepositories and Biospecimen Research (OBBR) is pleased to announce a new funding opportunity available under its cancer Human Biobank (caHUB) initiative.
Through an advanced network of tissue acquisition, biorepository operations, pathology review, and bioinformatics capabilities, caHUB will provide the high-quality, clinically annotated biospecimens that are essential resources to accelerate the development of molecular-based diagnostics and therapeutics for personalized medicine. This funding is made available under the American Recovery and Reinvestment Act of 2009 (Recovery Act), Pub. L. No. 111-5.
The caHUB is seeking to establish a centralized comprehensive biospecimen resource (CBR) to manage the collection, processing and distribution of high-quality caHUB biospecimens, derivatives and data. This Request for Proposals (RFP) is to solicit technical capabilities responses from entities that have the ability to serve as a caHUB CBR, providing biospecimen collection; receipt; logistical and physical management; annotation; processing into molecular analytes and biospecimen derivatives; subdivision of tissue; blood fractionation; molecular, clinical, and histological characterization; and distribution of biospecimens, biospecimen derivatives and data to qualified caHUB customers. One or more Basic Ordering Agreements (BOA) will be awarded to organizations capable of providing these core services.
This BOA RFP (No. S10-1035) is posted to Federal Business Opportunities at www.fbo.gov, under Solicitation Number: ST10-1035.
A preproposal teleconference will be held on June 1, 2010, from 1:00-3:00 p.m. EDT. This call will provide offerors the opportunity to ask questions about the RFP and receive answers during the teleconference.
Proposals are requested by June 17, 2010.
Request for Input on the Biospecimen Procurement Program for the NCI’s cancer Human Biobank
Under its Prime Contract with the National Cancer Institute (NCI) and on behalf of the NCI’s Office of Biorepositories and Biospecimen Research (OBBR), SAIC-Frederick, Inc. (SAIC-F) has issued a Pre-Solicitation Notice (Request for Information) for work in support of the caHUB under the American Recovery and Reinvestment Act (ARRA). A formal solicitation to identify potential Tissue Source Sites (TSS) to provide human cancer biospecimens (and associated normal controls) is expected to be published in the second quarter of 2010.
The purpose of this Pre-Solicitation Notice (Request for Information) is to:
- Convey the intent of the NCI OBBR to collect biospecimens and associated data for the caHUB.
- Seek input and comments regarding the concept, organization, and operational aspects of the program.
The Pre-Solicitation Notice is posted to http://www.fbo.gov/, under solicitation number ST10-1039. Additional details pertaining to this effort may be found in the notice, to which the draft Statement of Work is attached.
Responses to the Pre-Solicitation Notice are due by 12:00 p.m. (EDT) on April 23, 2010.
New Funding Opportunity: caHUB Acquisition of Normal Tissues
Preproposal Teleconference: Feb. 26, 2010, 1:00-3:00 p.m. EST
Receipt Date: March 12, 2010, 4:00 p.m. EST
The National Cancer Institute Office of Biorepositories and Biospecimen Research is pleased to announce a new funding opportunity available under its cancer Human Biobank (caHUB) initiative.
Through an advanced network of tissue acquisition, biorepository operations, pathology review, and bioinformatics capabilities, caHUB will develop the high quality, clinically annotated biospecimens that are essential resources to accelerate the development of molecular-based diagnostics and therapeutics for personalized medicine. The collection of normal human tissues is an important part of this effort, as such tissues are essential to the study of cancer and other diseases. The National Institutes of Health’s Genotype-Tissue Expression (GTEx) project, a NIH Roadmap initiative (http://nihroadmap.nih.gov/GTEx/), aims to provide a resource to the scientific community with which to study the relationship between genetic variation and regulation of gene expression. This project will analyze multiple human tissues from donors who will also be characterized for germline genetic variation through dense genotyping. caHUB will acquire normal tissues for the GTEx project through contracts with organizations such as rapid autopsy programs, organ and tissue transplant programs, surgical tissue procurement programs, and medical examiner programs.
This Request for Proposals (RFP) is to solicit technical capabilities responses from entities that have the ability to serve as a Tissue Source Site (TSS), providing clinically annotated normal human biospecimens to caHUB and GTEx. One or more Basic Ordering Agreements (BOA) will be awarded to organizations capable of accruing and delivering targeted normal biospecimens and their associated clinical data. The biospecimens and data will be delivered to caHUB for quality control, extensive pathology characterization, diagnostic verification, processing into molecular analytes, storage, other relevant processes, and distribution for qualified research and development.
The BOA RFP (No. S10-084) is posted to http://www.fbo.gov/, under solicitation number S10-084.
Offerors responding to the BOA RFP are also encouraged to respond to RFP No. S10-120, “caHUB Acquisition of Normal Tissues in Support of GTEx,” also currently posted to http://www.fbo.gov/, under solicitation number S10-120. RFP No. S10-120 represents the first Task Order issued under the umbrella of this BOA. Offerors responding to RFP No. S10-120 (GTEx) must also respond to the BOA solicitation, in order to be eligible for funding of the GTEx task order.
A preproposal teleconference was held on Feb. 26, 2010, from 1:00-3:00 p.m. EST. This call provided offerors the opportunity to ask questions about the RFP and receive answers during the teleconference.
Proposals are requested for the BOA and the GTEx task order by March 12, 2010.